ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
LOS ANGELES and SINGAPORE, Aug. 7, 2012 /PRNewswire/ — ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has signed a Master Service Agreement (MSA) with Singapore Radiopharmaceuticals Pte Ltd, a subsidiary of Fortis HealthCare.
“This agreement represents an important component of our expansion program in Singapore as we establish R&D and pre-clinical imaging capabilities there,” said Christian Behrenbruch, Ph.D., Chief Executive Officer of ImaginAb. “Singapore Radiopharmaceuticals has an excellent track record in custom radiochemistry and cGMP product manufacturing and we are pleased to transition our ad hoc collaboration to a more robust alliance.”
ImaginAb’s technology enables antibodies to be re-engineered into smaller proteins (fragments) with fast kinetics suitable for diagnostic imaging, while maintaining target biospecificity. In this way, true companion in vivo diagnostics can be rapidly developed that enable target expression to be profiled in tissues in a non-invasive, whole-body manner. ImaginAb has over a dozen development programs with global biopharma companies to develop companion diagnostic imaging agents to therapeutic antibody drugs (in Phase I to BLA), as well as an internal pipeline targeting unmet clinical needs, such as the staging of metastatic prostate and pancreatic cancer.*
“ImaginAb has an exciting product pipeline and an extensive pharma client base in need of cGMP radiochemistry services for clinical trials in all corners of the world,” said Dr. Nevil Chimon, CEO of Singapore Radiopharmaceuticals. “ImaginAb’s presence in Singapore is a visible part of Singapore’s growing footprint in molecular imaging and nuclear medicine.”
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company’s proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb’s technology is positioned to deliver on the promise of personalized medicine by improving patient outcomes and reducing the cost of healthcare. For more information, visit www.imaginab.com.
About Singapore Radiopharmaceuticals Pte Ltd
Founded in 2008 and part of the RadLink Group Asia, SRP provides GMP-compliant radiopharmaceuticals production using the GE 16.5 MeV PETtrace cyclotron and synthesis modules. Bespoke radiolabeling services include the use of Zirconium-89, Iodine-124 and Indium-111 isotopes. The company specializes in cGMP manufacture of proprietary tracers for clinical trials. SRP is dedicated to supplying beyond FDG tracers to all government and private hospitals in Singapore whilst supporting drug discovery programs for the pharmaceuticals industry. For more information, visit www.srp.com.sg
*the products and services described in this press release have not attained regulatory approval for clinical use in USA, UK/EU or Singapore.
SOURCE ImaginAb, Inc.